Clinical Trials Browser

Phase 1/2 × Completed × atezolizumab × Clear all

Small Cell Lung Carcinoma

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Neoplasm Metastasis

Esophageal Neoplasms

Carcinoma, Hepatocellular

Pancreatic Adenocarcinoma

Breast Neoplasms

Biliary Tract Neoplasms

Glioblastoma, Gliosarcoma

Squamous Cell Carcinoma of Head and Neck

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

Fallopian Tube Neoplasms, Ovarian Neoplasms

Rectal Neoplasms

Breast Neoplasms

Leukemia, Myeloid, Acute

Lymphoma, Large B-Cell, Diffuse

Triple Negative Breast Neoplasms

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Glioblastoma

Multiple Myeloma

Lymphoma, Follicular

Ovarian Neoplasms

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Carcinoma, Non-Small-Cell Lung

Clinical Trials

VENEZO-LUNG

COTESARC

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

TEMPLE

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

MORPHEUS HR+BC

COMBATBIL

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Study to Evaluate CCS1477 in Advanced Tumours

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

R-IMMUNE

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

ZUMA-6

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

FIDES-02

N²M²

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

AdORN

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

DARZALEX